Other clinical trials in sufferers with non-Hodgkin's lymphoma [24] and people with Innovative malignancy [fourteen] have shown also that zosuquidar didn't considerably impact the pharmacokinetics of doxorubicin and had reasonable outcomes over the pharmacokinetics of vincristine. These medical trials permitted that zosuquidar could safely administ